SEARCH

SEARCH BY CITATION

References

  • Adamou JE, Heinrichs JH, Erwin AL et al. (2001) Identification and characterization of a novel family of pneumococcal proteins that are protective in sepsis. Infect Immun 69: 949958.
  • Avery OT, MacLeod CM & McCarty M (1944) Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a deoxyribonucleic acid fraction isolated from Pneumococcus type III. J Exp Med 79: 137158.
  • Beghetto E, Pucci A, Minenkova O, Spadoni A, Bruno L, Buffolano W, Soldati D, Felici F & Gargano N (2001) Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries. Int J Parasitol 31: 16591668.
  • Beghetto E, Spadoni A, Buffolano W, Del Pezzo MA, Minenkova O, Pavoni E, Pucci A, Cortese R, Felici F & Gargano N (2003) Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Int J Parasitol 33: 163173.
  • Beghetto E, Nielsen HV, Del Porto P, Buffolano W, Guglietta S, Felici F, Petersen E & Gargano N (2005) A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts. J Infect Dis 191: 637645.
  • Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D & Malinoski F (2001) Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 20: 11051107.
  • Bogaert D, De Groot R & Hermans PW (2004a) Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect Dis 4: 144154.
  • Bogaert D, Sluijter M, De Groot R & Hermans PW (2004b) Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine 22: 40144020.
  • Briles DE, Hollingshead SK, Nabors GS, Paton JC & Brooks-Walter A (2000) The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19: S87S95.
  • Butler JC, Shapiro ED & Carlone GM (1999) Pneumococcal vaccines: history, current status, and future directions. Am J Med 107: 69S76S.
  • Chiavolini D, Memmi G, Maggi T, Iannelli F, Pozzi G & Oggioni MR (2003) The three extra-cellular zinc metalloproteinases of Streptococcus pneumoniae have a different impact on virulence in mice. BMC Microbiol 3: 14.
  • Dagan R, Isaachson M, Lang R, Karpuch J, Block C & Amir J (1994) Epidemiology of pediatric meningitis caused by a Haemophilus influenzae type b, Streptococcus pneumoniae and Nesseria meningitidis in Israel. J Infect Dis 169: 912916.
  • Di Cristina M, Del Porto P, Buffolano W, Beghetto E, Spadoni A, Guglietta S, Piccolella E, Felici F & Gargano N (2004) The Toxoplasma gondii bradyzoite antigens BAG1 and MAG1 induce early humoral and cell-mediated immune responses upon human infection. Microbes Infect 6: 164171.
  • Ejstrud P, Hansen JB & Andreasen DA (1997) Prophylaxis against pneumococcal infection after splenoctomy: a challenge for hospitals and primary care. Eur J Surg 163: 733738.
  • Fedson DS, Anthony J & Scott G (1999) The burden of pneumococcal disease among adults in developed and developing countries: what is known and what is not known. Vaccine 17: S11S18.
  • Gosink K, Mann ER, Guglielmo C, Tuomanen EI & Masure HR (2000) Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun 68: 56905695.
  • Hamel J, Charland N, Pineau I, Ouellet C, Rioux S, Martin D & Brodeur BR (2004) Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 72: 26592670.
  • Hausdorff WP, Feikin DR & Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5: 8393.
  • Horton RM, Cai Z, Ho SN & Pease LN (1990) Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8: 528532.
  • Hoskins J, Alborn WE Jr, Arnold J et al. (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 183: 57095717.
  • Iannelli F, Pearce BJ & Pozzi G (1999) The type 2 capsule locus of Streptococcus pneumoniae. J Bacteriol 81: 26522654.
  • Kausmally L, Johnsborg O, Lunde M, Knutsen E & Havarstein LS (2005) Choline-binding protein D (CbpD) in Streptococcus pneumoniae is essential for competence-induced cell lysis. J Bacteriol 187: 43384345.
  • McDaniel LS, Sheffield JS, Swiatlo E, Yother J, Crain MJ & Briles DE (1992) Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathogen 13: 261269.
  • Minenkova O, Pucci A, Pavoni E et al. (2003) Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 106: 534544.
  • Novak R, Charpentier E, Braun JS, Park E, Murti S, Tuomanen E & Masure R (2000) Extracellular targeting of choline-binding proteins in Streptococcus pneumoniae by a zinc metalloprotease. Mol Microbiol 36: 366376.
  • Obaro SK (2002) The new pneumococcal vaccine. Clin Microbiol Infect 8: 623633.
  • Pearce BJ, Iannelli F & Pozzi G (2002) Construction of new unencapsulated (rough) strains of Streptococcus pneumoniae. Res Microbiol 153: 243247.
  • Rapola S, Jantti V, Haikala R et al. (2000) Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 182: 11461152.
  • Sambrook J & Russell DW (2001) Molecular Cloning: A Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  • Santini C, Brennan D, Mennuni C, Hoess RH, Nicosia A & Cortese R (1998) Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda. J Mol Biol 282: 125131.
  • Schneewind O, Mihaylova-Petkov D & Model P (1993) Cell wall sorting signals in surface proteins of gram-positive bacteria. EMBO J 12: 48034811.
  • Shoemaker NB & Guild WR (1974) Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation. Mol Gen Genet 128: 283290.
  • Tuomanen EI (2000) Pathogenesis of pneumococcal inflammation: otitis media. Vaccine 19: S38S40.
  • Virolainen A, Russel H, Crain MJ, Rapola S, Kaythy H & Briles DE (2000) Human antibodies to pneumococcal surface protein A in health and disease. Pediatr Infect Dis J 19: 134138.